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A hallmark of rheumatoid arthritis is the formation of an aggres-
sive, tumor-like structure called pannus that erodes the joint. A
major cellular component of the pannus is the fibroblast-like
synoviocyte (FLS), whose morphology strikingly resembles that of
a transformed cell, but underlying mechanisms of this ‘‘transfor-
mation’’ are not known. Here, using animal models of rheumatoid
arthritis, we show that arthritic FLS contain a substantial (>30%)
fraction of bone marrow-derived precursors that can differentiate
in vitro into various mesenchymal cell types, but inflammation
prevents the multilineage differentiation. We show that the tran-
scription factor NF-B plays the key role in the repression of
osteogenic and adipogenic differentiation of arthritic FLS. Further-
more, we show that specific activation of NF-B profoundly en-
hances proliferation, motility, and matrix-degrading activity of FLS.
We thus propose that arthritic FLS are mesenchymal stem cells
whose differentiation is arrested at early stages of differentiation
by activation of NF-B.
fibroblast-like synoviocytes  mesenchymal stem cell  rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory diseasethat mainly affects joints. Hallmarks of RA pathology are
chronic inflammation and pronounced synovial hyperplasia. Nor-
mal synovial membrane is a delicate tissue structure that lines the
joint cavity and is comprised of one to two layers of cells. Two major
populations of resident synoviocytes can be distinguished: macro-
phage-like (or type A) synoviocytes and fibroblast-like (or type B)
synoviocytes (FLS). Onset of RA causes dramatic morphological
changes in the synovial membrane, including a thickening of the
intimal lining and the formation of an aggressive, tumor-like
structure called pannus that invades and erodes the cartilage and
the subchondral bone (1).
The pannus is comprised of many cell types, including inflam-
matory, immune, and mesenchymal cells. The latter, referred to as
RA FLS, play a major role in the invasive joint destruction by
producing large quantities of enzymes degrading the joint matrix.
The RA FLS resemble immature, transformed fibroblasts and are
in many ways different from normal FLS. Compared with normal
FLS, RA FLS have higher proliferation rates and are highly
invasive. Unlike normal FLS, RA FLS invade and degrade cartilage
when coengrafted into appropriate animal strains (2, 3).
The mechanisms underlying the tumor-like phenotype of RA
FLS are poorly understood. There have been attempts to explain
the tumor-like phenotype of RA FLS by dedifferentiation of
normal FLS, presumably through an accumulation of genetic and
epigenetic abnormalities, similar to that occurring in cancer (4). In
support of this hypothesis, a number of protooncogenes, including
myc, ras, and fos, are overexpressed in RA FLS (5), albeit no
common genetic abnormalities in these genes have been identified.
Somatic mutations in the tumor-suppressor gene p53 were associ-
ated with RA FLS (6), but a role for these mutations to the
‘‘pseudotransformed’’ RA FLS phenotype is not known. Another
point against the ‘‘transformation’’ hypothesis is the slowing of the
rapid growth of RA FLS after several passages in culture (7).
The origin of RA FLS is also matter of debate. According to one
theory, RA FLS stem from normal FLS. According to another
hypothesis, RA FLS are subintimal fibroblasts that migrated to the
RA synovium and acquired the altered morphology (8). More
recently, it was found that a fraction of the heterogeneous RA FLS
population has properties one usually associates with mesenchymal
stem cells (MSC). When stimulated in culture with appropriate
stimuli, a proportion of RA FLS can differentiate into chondro-
cytes, osteoblasts, adipocytes, and muscle cells (9, 10). Interestingly,
systemically injected purified MSC were shown to home to different
joint compartments, e.g., muscles, cartilage, and bones (11, 12).
In the present work we used animal models of RA to elucidate
contribution of bone marrow (BM)-derived MSC to synovial hy-
perplasia in arthritis and to examine the molecular mechanisms
underlying the abnormal phenotype of arthritic FLS. We show that
BM-derived MSC are present among FLS isolated from normal
joints and that the fraction of the BM-derived mesenchymal cells
dramatically increases with the onset of arthritis. Furthermore, we
demonstrate that differentiation of arthritic FLS into osteoblasts or
adipocytes can be prevented by inflammatory cytokines, e.g., IL-1,
and the activation of the transcription factor NF-B appears
necessary and sufficient for the suppression of differentiation.
Furthermore, specific activation of the NF-B pathway alone
dramatically increases FLS proliferation and produces a highly
invasive cell phenotype characterized by a profound increase in cell
motility and by constitutive secretion of active matrix metal-
loproteinases (i.e., MMP-13). These data suggest that synovial
hyperplasia in arthritis occurs because of an impairment of a normal
physiological mechanism that provides the repair of joint tissues.
That is, we propose that RA FLS are bona fide BM-derived
pluripotent mesenchymal cells that are recruited to the arthritic
joint in large quantities and are arrested at various stages of
differentiation by inflammation. The activation of NF-B appears
to play the central role in the differentiation block, as well as in the
maintenance of the high invasiveness and abnormal motility of the
recruited cells.
Results
Normal FLS Contain a Minor Fraction of BM-Derived Mesenchymal
Cells. When purified MSC are injected in circulation or i.p., pro-
genitors of these cells can be found in different joint compartments,
including muscles and bone (11, 13). However, because the normal
physiological levels of MSC in circulation are extremely low, the
high concentrations of administered MSC may produce artificial
results. Thus, we used another model, i.e., BM transplantation
(BMT) of BM cells from GFP-transgenic donor mice into lethally
irradiated GFP-negative recipients (14, 15). To assess GFP-positive
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mesenchymal cells in joints, primary FLS from synovial explants
were isolated at 2 months after transplantation. As the rapidly
dividing FLS overgrow nondividing macrophage-like synoviocytes,
the vast majority of cell culture after two to three passages is
represented by mesenchymal cells (1). We found that, at a third
passage, GFP-positive cells had a fibroblast-like appearance and
comprised 1.2  0.2% of the FLS population (Fig. 1). Thus, a minor
fraction of FLS in normal joints is represented by BM-derived
mesenchymal precursors.
Migration of BM-Derived Mesenchymal Cells into the Joint Dramati-
cally Increases in Arthritis. Antigen-induced arthritis in the GFP
BMT mice was induced by immunizing the animals with intrader-
mal injection of methylated BSA (mBSA) followed by an intraar-
ticular (i.a.) injection of mBSA 3 weeks later. Three more days later,
FLS cells were isolated by dispersal of synovial explants from the
antigen-induced arthritis joints. At the third passage, GFP-positive
cells comprised a substantial fraction (33.7  1.6%) of the arthritic
FLS (Fig. 1). Therefore, arthritis development resulted in a dra-
matically increased influx of BM-derived mesenchymal cells into
synovium.
Inflammatory Cytokines Prevent Differentiation of Arthritic FLS
Through the Activation of NF-B. One hallmark of RA joints is a high
concentration of inflammatory cytokines TNF and IL-1. It is
known that both TNF and IL-1 can inhibit the multilineage
differentiation of transformed MSC lines, e.g., C2C12 and
C3H10T12 cells (16, 17). Because primary cultures of RA FLS
have a fraction of pluripotent cells that can differentiate into
chondrocytes, osteoblasts, adipocytes, and muscle cells (9, 10), we
examined whether inflammation could also affect differentiation of
arthritic FLS. In these experiments we used primary FLS derived
from rats (rFLS) with PG-PS-induced arthritis (instead of mouse
FLS from the BMT GFP mice of which we had rather limited
supply). We found that, upon incubation in an adipogenic medium,
a proportion of rFLS had differentiated into adipocytes. The
adipocyte differentiation was practically abolished by addition of
IL-1 to the adipogenic medium (Fig. 2A a–c).
The transcription factor NF-B is a common downstream target
of both TNF and IL-1 that has been implicated into multiple
aspects of RA joint pathology (18, 19). NF-B activation is also
known to inhibit multiple pathways of MSC differentiation, includ-
ing the chondrocytic, myoblast, and adipocytic differentiation (16,
17). The role for NF-B in osteogenic differentiation is less known,
and some observations suggest that the activation of NF-B may
rather promote the osteogenic differentiation (20). To assess the
potential role for NF-B in differentiation of arthritic FLS, we
infected the cells with an adenovirus vector constitutively express-
ing ‘‘superrepressor’’ IB (21), a nondegradable form of IB that
potently inhibits NF-B (22). In the presence of srIB, IL-1
failed to block the adipogenic differentiation, indicating that NF-B
activation was required for the ‘‘antidifferentiating’’ activity of
IL-1 (Fig. 2A c and d).
Because NF-B is one of many downstream targets of inflam-
matory cytokines, we assessed whether NF-B activation would be
sufficient to prevent differentiation of FLS. To selectively activate
NF-B, we used two approaches. In one approach, cells were
transduced with a retroviral vector (RV) expressing RelA, a
transcriptionally active subunit of NF-B (Fig. 2B). In another
approach, cells were transduced with a RV expressing a constitu-
tively active form of IB kinase  [IKK(EE)] (23) that catalyzes the
phosphorylation-dependent degradation of IB (Fig. 2 B and C).
Both approaches caused a sustained NF-B activation, as evidenced
by elevated NF-B-dependent reporter gene transcription
(Fig. 2D).
Initially we examined the role for NF-B in adipogenic differ-
entiation of rFLS. When incubated in an adipogenesis-inducing
medium (MDI), a fraction of rFLS with an empty pBabe vector
underwent adipogenic differentiation, as evidenced by lipid accu-
mulation (Fig. 2E) and by the expression of PPAR2, a marker of
adipogenic differentiation (Fig. 2F). The adipogenic differentiation
was potently inhibited by ectopic expression of CA IKK (Fig. 2 E
and F) and of RelA (data not shown).
To determine whether this antidifferentiation role of NF-B was
restricted to the particular (adipogenic) differentiation pathway, we
examined the osteogenic differentiation of rFLS. We found that the
selective activation of NF-B also prevented the osteogenic differ-
entiation. When cultured in an osteogenic medium, a substantial
fraction of rFLS transduced with the control (Babe) retrovirus
underwent the osteogenic differentiation, as evidenced by in-
creased enzymatic activity of alkaline phosphatase (ALP) (Fig. 3 A
and B), by calcium deposition (Fig. 3 C and D), and by increased
expression of the osteoblast differentiation markers osteopontin
(Fig. 3E) and osteocalcin (data not shown). The osteogenic differ-
entiation was potently inhibited by ectopic expression of either
RelA or CA IKK (Fig. 3). Therefore, the activation of NF-B
appeared sufficient to inhibit differentiation of rFLS into osteo-
blasts and adipocytes.
Constitutive NF-B Activation Accelerates FLS Proliferation. In an
earlier work we showed that NF-B activation in primary FLS was
required for transmitting mitogenic responses to platelet-derived
growth factor (24). Here we found that, in the absence of growth
factors, NF-B activation alone was sufficient to accelerate FLS




Fig. 1. The presence of BM-derived cells in the populations of normal and
arthritic FLS. BM cells from GFP transgenic donor mice were transferred into
lethally irradiated GFP-negative recipient mice. Two months later, primary FLS
were established by an enzymatic dispersal of synovial explants of the recipient
BMT mice. p1 and p3, the first and third passages of primary FLS. The first and
third rows represent phase-contrast microscopy; the second and fourth rows
represent fluorescent microscopy. Normal, primary FLS that were obtained from
normal joints of the BMT mice. At the third passage, GFP-positive cells comprised
1.2  0.2% of the population of normal FLS (mean  SEM of two experiments).
Arthritic, primary FLS that were obtained from arthritic BMT recipient mice as
described in Materials and Methods. At the third passage, GFP-positive cells
comprised 33.7  1.6% of the population of arthritic FLS (mean  SEM of three
experiments). (Original magnification: 100.)











by MTT assay (Fig. 4A a and b). The FLS with constitutively active
NF-B had shorter doubling time (26.8  0.5 h in CA IKK-RV
transduced FLS vs. 50  4 h in control FLS transduced with an
empty RV; P  0.005) (Fig. 4Ac). The overexpression of RelA also
somewhat shortened the doubling time (37  7 h vs. 50  4 h in
control cells), but this was not a statistically significant difference
(P  0.167) (Fig. 4Ac).
Constitutive NF-B Activation Stimulates the Production of Active
MMP-13 by FLS. One mechanism whereby RA FLS contribute to
destruction of the cartilage and bone is through secretion of large
quantities of MMPs. Promoters of many MMPs (e.g., MMP-1,
MMP-3, and MMP-13) contain NF-B binding sites that are
required for their transcriptional activation by inflammatory cyto-




































































Fig. 2. NF-B activation is necessary and
sufficient to inhibit the adipogenic differen-
tation of arthritic rFLS. (A) NF-B is required
for the antidifferentiating activity of IL-1 in
the adipogenic differentiation of arthritic
rFLS.PrimaryFLSfromratswithPG-PS-induced
arthritis were infected with a control,
‘‘empty’’ adenovirus (Control) (a–c) or with
adenovirus expressing superrepressor IB
(AdsrIB) (d). Cells were incubated in DMEM
(a) or in an adipogenesis-inducing medium
(MDI) (b), or in the MDI medium in the pres-
ence of IL-1 (100 unitsml) (c and d). After 21
days, differentiated cells were visualized by
stainingtheaccumulated lipidswithanOil red
stain. Representative data of three experi-
ments are shown. (Original magnification:
100.) (B–D) Constitutive activation of NF-B
by retrovirus-mediated gene transfer of a
dominant-positive IKK and RelA. Primary
rFLS were transduced with a control RV Babe
(control Babe) or with vectors that expressed
cDNA of FLAG-tagged constitutively active
IKK mutant [IKK(EE)], or FLAG-tagged RelA
cDNA. After puromycin selection, NF-B acti-
vation was assessed. (B) The expression of ex-
ogenous IKK(EE) and RelA proteins was as-
sessed by immunoblotting with anti-FLAG Ab.
(C) The expression of IKK(EE) results in accu-
mulation of a phosphorylated form of IB.
The control (Babe) and IKK(EE) cells were de-
tected by using antiphospho IB Ab. Where indicated, cells were pretreated with a proteasomal inhibitor, MG132, to allow for accumulation of the phosphorylated
IB. (D) Ectopic expression of IKK(EE) and RelA induces constitutive activation of NF-B-driven gene expression. Transduced rFLS were transiently cotransfected with
an NF-B-inducible reporter vector expressing the firefly luciferase and a constitutively active reporter expressing the Renilla luciferase. Normalized values of NF-B
activation from duplicated samples are shown. Representative data of two experiments are shown. (E and F) Constitutive activation of NF-B inhibits the adipogenic
differentiation of arthritic rFLS. (E) RV-transduced cells (as in B) were incubated in a control medium (DMEM) or in an adipogenesis-inducing medium (MDI). After 21
days, the adipogenic differentiation was assessed by staining accumulated lipids with Nile red. The staining was visualized by fluorescent microscopy (Left). (Original
magnification: 100.) Cells were counterstained with the nuclear stain Hoechst 33342 (Right). (F) The expression of an adipogenic differentiation marker (PPAR2) was








































Fig. 3. Constitutive activation of NF-B inhibits osteo-
genic differentiation of arthritic rFLS. RV-transduced cells
(as in Fig. 2B) were incubated in a control medium
(DMEM) or in an osteogenesis-inducing medium (OS). (A)
The activity of ALP in the control (Babe) and in RelA-
transduced cells after 14 days of incubation. (B) ALP ac-
tivity in the control and IKK(EE)-transduced cells after 14
days of incubation. (C) Mineral deposition in the control
(Babe) and in IKK(EE)-transduced cells after 21 days of
incubation, as assessed by silver staining. (Original mag-
nification in A and C: 100.) (D) Calcium deposition in
cells shown in C was quantitatively assessed and normal-
ized on protein content. (E) The expression of an osteo-
genic differentiation marker (osteopontin) in cells shown
in B as assessed by RT-PCR.
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(25, 26). Like most MMPs, the MMP-13 is secreted as a proenzyme
that has to be clipped to become an active enzyme. In our hands,
IL-1 caused a moderate (if any) increase in the production of
pre-MMP-13 in FLS, but constitutive activation of NF-B (in CA
IKK- or RelA-overexpressing cells) strongly potentiated the in-
duction of MMP-13 by IL-1 (Fig. 4B). Quite unexpectedly, the
constitutive activation of NF-B also strongly enhanced the pro-
duction of active MMP-13, the effect particularly pronounced in
RelA-overexpressing cells, wherein large amounts of active
MMP-13 were evident even in the absence of IL-1 stimulation (Fig.
4B). This suggests NF-B-dependent mechanism(s) that act inde-
pendent of the transcriptional activation of MMP-13 gene tran-
scription by accelerating the processing of the MMP-13 proenzyme.
Constitutive NF-B Activation Enhances FLS Motility. Cell motility is
another factor determining cells’ invasiveness. For example, in-
creased motility casually relates to increased invasiveness and
metastasis of cancer cells. We used a transwell migration assay to
assess an impact of constitutively active NF-B on FLS motility. The
overexpression of RelA had a weak effect (1.5-fold increase of the
motility), whereas the overexpression of CA IKK had a dramatic
effect on the motility (a 6.5-fold increase over the control cells) (Fig.
4C). Combined with data on enhanced production and processing
of MMP-13, these results suggest that activation of NF-B strongly
enhances the invasiveness of FLS.
Discussion
The RA FLS differ in many aspects from the normal FLS. One of
the most pronounced phenotypic features is the high invasiveness
of RA FLS that correlates with the elevated production of inflam-
matory cytokines and MMPs. Under appropriate conditions, this
phenotype can be sustained for many weeks: for example, unlike
their normal counterparts, RA FLS, being coengrafted with a piece
of cartilage in renal cavity of permissive mouse, invade and erode
the cartilage (2, 5). The highly invasive phenotype as well as
elevated expression of protooncogenes, matrix proteinases, and
accumulation of DNA mutations in RA FLS are similar to that
occurring in transformed fibroblasts, hence the attempts to explain
the RA FLS phenotype by a pseudotransformation of normal FLS,
presumably stemming from the chronic exposure of these cells to
the inflammatory environment of RA joints (1, 4). According to
this theory, the RA FLS represent dedifferentiated progenitors of
resident FLS. However, the pseudotransformation hypothesis has
many difficulties, e.g., the molecular mechanisms underlying this
‘‘dedifferentiation’’ are yet to be shown. We propose here an
alternative explanation.
Under normal physiological conditions, the musculoskeletal
system is subjected to persistent mechanical stress. To keep the
physiological wearing and tearing in check, there are repair mech-
anisms that renew the damaged tissues, and BM-derived MSC
appear central to this process. For example, it is well established that
muscle damage stimulates influx of MSC into the muscle compart-
ment, the influx being commensurate with the damage. The
recruited MSC differentiate into myoblasts thereby repairing the
damage (13). Because MSC can also differentiate into chondro-
cytes, osteoblasts, adipocytes, and other mesenchymal cell types,
similar mechanisms should operate to provide the repair of the
bone, cartilage, and other tissues of the joint under the normal
physiological conditions. The recruited MSC receive microenviron-
mental clues that instruct cells to differentiate into corresponding
cell types (chondrocytes, osteoblasts, ‘‘normal’’ FLS, etc.). The
intensity of the damage signals should be commensurate with
wearing and tearing of joint tissues so that MSC influx would be
appropriately regulated (Fig. 5A).
We postulate that diverse arthritopathogenic stimuli, e.g.,
chronic viral or bacterial infection or persistent bacterial products,
may produce persistent and elevated levels of damage signals,
presumably through inducing chronic inflammation in the joint
space. The persisting damage signals will perpetuate MSC influx to
the joint. On the other hand, inflammatory milieu in arthritic joints
induces and maintains NF-B activation in the recruited MSC,
thereby blocking the microenvironmental differentiation signals
and sustaining cells in an underdifferentiated state (Fig. 5B).
Therefore, according to this model, the RA FLS appear bona fide
MSC that are arrested at various stages of differentiation into
different lineages.
According to our hypothesis, RA FLS appear as underdifferen-
tiated precursors, rather than dedifferentiated progenitors, of res-
ident FLS cells. In line with that, we believe that ‘‘pannocytes,’’
another primary cell type isolated from the pannuscartilage in-
terface of RA joints (whose transient phenotype resembles both
chondrocytes and fibroblasts) (10), may be considered as MSC
arrested in intermediate stages of chondrogenic differentiation.
Although we focused on only the osteogenic and adipogenic
differentiation of primary FLS, experimental data by others (in
transformed MSC cell lines) suggest that inflammation-inducible










































































































































Fig. 4. Constitutive activation of NF-B accelerates cell growth and enhances
the invasiveness of arthritic rFLS. (A) Constitutive activation of NF-B accelerates
cell growth. Cells were transduced as described for Fig. 2B, and proliferation was
assessed by determining thymidine incorporation (a) or by MTT proliferation
assay (b). (Ac) To directly assess cell growth, cells were plated at a low density and
counted after 5 days in culture. The numbers of cells was adjusted to plating
efficacy that was assessed 1 day after plating. Doubling times were calculated
assuming an exponential cell growth. Representative data of three experiments
are shown. *, P  0.05 vs. Babe control. (B) The production of preproactive and
active forms of MMP-13 protein by transduced cells was assessed by immuno-
blotting in lysates of cells that were unstimulated or stimulated for 4 h with IL-1
(100 unitsml). The blot was reprobed with -actin Ab. (C) Constitutive activation
of NF-B enhances invasiveness. Cell motility was assessed in a transwell cell
migration assay as described in Materials and Methods. The cells that migrated
through the filter were stained and counted. One representative experiment























Fig. 5. Constitutive activation of NF-B in arthritic joints maintains the highly
invasive, undifferentiated phenotype of arthritic FLS.











drogenic) differentiation pathways (16, 17). Thus, we expect that a
thorough examination of primary RA FLS cell cultures may reveal
other transient phenotypes, e.g., fibroblastsosteoblasts, fibro-
blastsadipocytes, fibroblastsmyoblasts, etc.
Another corollary of our model is that neutralizing the damage
signals may have therapeutic effects in RA. This brings the question
about the nature of the damage signals in the normal and in RA
joints. Among the soluble cytokines that may serve as a damage
signal, one evident candidate is the inflammatory cytokine TNF.
For example, it has been shown that, in mice with collagen-induced
arthritis, the canals connecting the joint space with the BM com-
partment are enlarged, resulting in an enhanced migration of BM
cells to the joint, whereas TNF inhibitors inhibited the migration
(12). However, this does not rule out a role for other chemokines
in regulating the recruitment of BM-derived MSC into the joints
(through the canals or from the circulation). It would be also of
interest to investigate the role of the chemokine receptors that
mediate the recruitment of leukocytes to RA joints and to assess a
possible involvement of these receptors in the recruitment of the
mesenchymal cells. NF-B may play an important role in the
generation of the damage signals, owing to the essential role for
NF-B in chronic inflammation (27).
Our results indicate a central role for NF-B in RA FLS
differentiation. A pivotal role of NF-B in inflammatory responses
has been well established, so that NF-B became synonymous with
chronic inflammation and is considered a hallmark of RA pathol-
ogy. Others and we have shown the numerous roles for NF-B in
many aspects of RA pathology (inflammation, T cell activation,
FLS proliferation, and apoptosis) (18). Here we demonstrate yet
another mechanism whereby NF-B contributes to RA pathology.
We show that NF-B activation prevents the multilineage pathways
of RA FLS differentiation while dramatically increasing the pro-
liferation, the motility, and the production of active MMP-13.
Therefore, NF-B is central to the invasive phenotype one associ-
ates with RA FLS.
There is an evident implication of our study for the development
of treatments targeting RA-associated bone resorption. Bone tissue
turnover is controlled by the balance of two processes, i.e., the bone
resorption (mediated by osteoclasts) and bone synthesis (mediated
by osteoblasts). It is well known that NF-B activation in hemato-
poietic precursors promotes the osteoclast differentiation (e.g., by
mediating RANK-induced signaling) and increases the osteolytic
activity of osteoclasts (28). Opposite to that, our results show that
NF-B activation in mesenchymal FLS inhibits the osteoblast
differentiation of arthritic FLS. Thus, using NF-B inhibitors, on
one hand, should block the osteoclast differentiation, and, on the
other hand, it should promote osteoblast differentiation and thus
may provide very efficacious treatment of RA-associated bone
resorption.
Interestingly, although NF-B suppression had similar effects on
osteogenic and adipogenic differentiation pathways, we found that,
by acting on different steps of the NF-B pathway in FLS, we had
produced somewhat different phenotypes. For example, inducing
constitutive activation of NF-B by overexpressing RelA had most
pronounced effect on MMP-13 secretion, whereas overexpressing
CA IKK most profoundly affected cell motility and proliferation.
Thus, it should be possible to tailor distinct NF-B inhibitors to
specific therapeutic applications by interfering at different points of
the signaling pathways that control NF-B activation (19).
The precise molecular mechanisms whereby NF-B activation
impinges on the multiple differentiation pathways in arthritic FLS
remain to be identified. The fact that NF-B activation was equally
important for different differentiation pathways suggests that there
may be a unified mechanism that acts in these pathways. In this
regard, recent publications indicate that NF-B can modulate the
differentiation of mesenchymal-derived cell lineages via RNA
sequence-dependent, posttranscriptional down-regulation of key
developmental regulators, including Sox9 and MyD (17).
In summary, our study suggests that the abnormal phenotype of
RA FLS may stem from an aberrant activation of mechanisms that
normally serve to provide physiological repair of joint tissues.
Arthritogenic stimuli provide aberrant production of damage sig-
nals that cause sustained influx of BM-derived MSC to the joint.
Thus, the RA FLS appear as a heterogeneous population of
underdifferentiated MSC that are arrested at intermediate stages of
differentiation by the inflammatory milieu. The sustained activa-
tion of NF-B plays a central role in blocking the multilineage
differentiation and in maintaining the highly invasive phenotype by
the RA FLS.
Materials and Methods
All tissue culture materials were from Gibco (Grand Island, NY).
Unless stated otherwise, all other chemicals were from Sigma (St.
Louis, MO). Human recombinant IL-1 and TNF were from
Roche Applied Science (Indianapolis, IN). MG132 was from
Peptides International (Louisville, KY). All work in animals was
carried out in strict accordance with the guidelines for humane care
and use of laboratory animals in University of North Carolina
(Chapel Hill).
BMT. The eGFP transgenic mice (on C57BL6 background)
wherein eGFP was ubiquitously expressed under the control of the
chicken -actin promoterCMV immediate early enhancer were a
gift from Jon Serody (University of North Carolina, Chapel Hill,
NC) (29). The BM cells were obtained from the eGFP transgenic
mice at the age of 2–3 months by flushing the cavity of tibias and
femurs. A single-cell suspension was obtained by centrifuging in
Ficoll-Paque Plus (Amersham Biosciences, Uppsala, Sweden). Re-
cipient C57BL6 mice (aged 8 weeks; Charles River Laboratories,
Wilmington, MA) were lethally irradiated with 9.5-Gy 60Co  rays.
Approximately 20 h after irradiation they received 1  106 donor
GFP positive BM cells intravenously. At 60 days after transplan-
tation, GFP-positive cells comprised 80% of BM cells and 92%
of circulating leukocytes in the recipient animals, as determined by
FACS analysis.
mBSA-Induced Arthritis. Antigen-induced arthritis in mice was in-
duced as described (30). Two months after the BMT, the recipient
mice were immunized intradermally at the base of the tail with 100
g of mBSA emulsified in 100 l of complete Freud’s adjuvant
containing 5 mgml H37RA Mycobacterium tuberculosis (Difco
Laboratories, Detroit, MI). Three weeks later, the primed mice
were i.a. injected with mBSA (20 g) at the knee joints. Three days
after the i.a. injection, primary FLS cultures were established from
synovial explants by enzymatic dispersal (24).
rFLS Cell Culture. Arthritic rFLS were isolated from joints of rats
with PG-APS-induced arthritis, as described (22). Synovium ex-
plants were obtained at a chronic phase of arthritis, digested with
collagenase IV in serum-free DMEM for 3 h at 37°C, filtered
through a nylon mesh, and incubated overnight in a humidified 5%
CO2 atmosphere at 37°C in a DMEM culture medium supple-
mented with 10% FBS, 2 mM glutamine, 100 unitsml penicillin,
and 100 gml streptomycin. After the removal of nonadherent
cells, adherent cells were cultivated in a fresh medium. Cells were
split at a 1:3 ratio. Cells from passages 3–8 were used in these
experiments.
Flow Cytometry and Cell Sorting. eGFP expression in BM cells and
in circulating leukocytes was analyzed by using MoFlo cell sorter
(Cytomation, Fort Collins, CO). Data were analyzed with Summit
software (Cytomation).
Retroviral Transduction and Adenoviral Infection. VSV-G
pseudotyped recombinant Moloney murine leukemia virus retro-
viruses were generated in E-23 cells packaging cell line that stably
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expressed gag and pol proteins (31). The packaging cells were
transiently cotransfected with an expression plasmid pVSVG car-
rying cDNA of the vesicular stomatitis virus envelope protein and
pBabe vector carrying cDNA of the transgene [human IKKEE
(177181EE) or wt RelA] and a Puro resistance marker gene (32).
The titers of the retrovirus in the supernatants were in the range of
3  105 to 3  106 cfuml. Cells were transduced by incubation with
retrovirus-containing supernatants in the presence of Polybrene
and selected in a medium containing 6 gml puromicin. Recom-
binant Ad5-based vector carrying the cDNA of superrepressor
IB (3236 AA) was described previously (22). Cells were infected
with the adenovirus at the multiplicity of infection of 200 particles
per cell.
Adipogenic and Osteogenic Differentiation. Postconfluent FLS were
incubated in adipogenic induction medium (MDI) as described
elsewhere (33). To induce osteogenic differentiation, FLS at 90%
confluence were incubation in osteogenesis-inducing medium con-
taining with 50 gml ascorbic acid, 100 nM dexamethasone, 10
mM -glycerol phosphate, and 10% FBS (33). On day 14, cells were
fixed and ALP expression was assessed with Diagnostic Kit 86 from
Sigma. At day 21, mineral deposition was assessed by staining with
2% silver nitrate according to the von Kossa method (34). In
parallel samples, deposited calcium was extracted in 0.5 N HCl for
24 h at 4°C and measured by using Sigma Diagnostic Kit 587
according to the manufacturer’s instructions.
Immunoblotting. Cell lysates were resolved on a 10% SDSPAGE
gel and transferred onto PVDF membranes. Immunodetection was
performed with Abs to IB Santa Cruz Biotechnology (Santa
Cruz, CA); to FLAG epitope and anti--actin; to phospho-IB
and anti-tubulin (Cell Signaling Technology, Danvers, MA), and
with secondary HRP-conjugated anti-rabbit or anti-mouse IgG Ab
(Santa Cruz Biotechnology). The detection was visualized by using
an ECL detection kit (PerkinElmer, Boston, MA).
Reporter Gene Assay. NF-B activity in FLS was assessed by using
an NF-B reporter gene construct, as described (22). For normal-
ization, cells were cotransfected with a constitutive Renilla lucif-
erase reporter (Promega, Madison, WI). Transfections were per-
formed with Effectene reagent (Qiagen, Valencia, CA). Two days
after transfection, the firefly and Renilla luciferase activities were
determined by dual luciferase assay system (Promega).
RT-PCR. Total RNA was extracted from cells by using TRIzol
extraction (Gibco Life Science, Rockville, MD) and was reversely
transcribed with SuperScript II reverse transcriptase (Invitrogen,
Carlsbad, CA). PCR amplification was done with the following
primers: PPAR2, 5-GTGACTTGGTGGTGATCTAG-3 (for-
ward primer) and 5-CGTTACAAGATTTATTCACACCA-3
(reverse primer); osteopontin, 5-TGT CTCCCGGTGAA-
AGTG-3 (forward primer) and 5-AGTCCATAAGCCAAGCT
ATC-3 (reverse primer); GAPDH, 5-TGAAGGTCGGTGT-
CAACGGATTTG-3 (forward primer) and 5-GTACATCCG-
TACTCCAGGTGGTG-3 (reverse primer). PPAR2 was ampli-
fied by 34 cycles of PCR at an annealing temperature of 55°C.
GAPDH and ostopontin were amplified at an annealing temper-
ature of 60°C by using 24 and 22 cycles, respectively. PCR products
were resolved and visualized by 1.5% agarose gel electrophoresis.
Cell Proliferation Assays. For [3H]thymidine incorporation, expo-
nentially growing FLS were plated into 12-well plates at 104 cells per
well. Three days later, [3H]thymidine (1 Ciml) was added for 8 h.
Harvested cells were washed, precipitated with 5% trichloroacetic
acid at 4°C, washed with ice-cold 95% ethanol, dried, and counted
with a radioactivity counter.
MTT Assay. Exponentially growing FLS were plated in into 12-well
plates in duplicate (4  104 cells per well). After 48 h, cell
proliferation was measured by a modified MTT assay (35).
In Vitro Invasion Assay. The invasion assay was adapted from a
procedure described previously (36). Matrigel (Becton Dickinson,
San Jose, CA) was diluted to 0.4 mgml in a serum-free DMEM and
layered on the top of polycarbonate filter insert (6.5-mm diameter,
8.0 m; Costar, Cambridge, MA) to form a gel at 37°C. FLS (2 
104 cells200 l) were loaded on the Matrigel-coated inserts and
transferred to a 24-well plate with 600 l of 0.5% FBS DMEM in
the lower compartment. After 3 days of incubation, the cells were
fixed in an ethanolcrystal violet solution. The number of cells that
crossed the transwell membrane was counted under a light micro-
scope. All experiments were done in duplicate.
Statistical Analysis. Unless otherwise indicated, all results are shown
as means  SEM. Statistical differences between groups were
determined by using ANOVA.
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